Rna replicon for improving gene expression and use thereof
US-2024417751-A1 · Dec 19, 2024 · US
Immune effector cells pre-infected with oncolytic virus
US9101658B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101658-B2 |
| Application number | US-201213470558-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 14, 2012 |
| Priority date | Sep 30, 2005 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer in a patient, the method comprising: administering systemically to a cancer patient at least 10 8 of human cytokine induced killer (CIK) cells infected with a oncolytic vaccinia virus in an extended eclipse phase, wherein the oncolytic vaccinia virus: (i) is replication competent, and (ii) comprises a genetic modification that substantially eliminates viral thymidine kinase (TK) and a genetic modification that substantially eliminates active viral growth factor (VGF); wherein tumor cells of the cancer are reduced or eliminated. 2. The method of claim 1 , wherein the patient has been previously immunized with vaccinia virus. 3. The method of claim 1 , further comprising the step of repeated administration to the patient of the human cytokine induced killer (CIK) cell population infected with said oncolytic vaccinia virus. 4. The method of claim 1 , wherein the cytokine induced killer (CIK) cell population is autologous to the patient. 5. The method of claim 1 , wherein the cytokine induced killer (CIK) cell population is allogeneic to the patient.
Assignees
Inventors
Classifications
Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00) · CPC title
Antineoplastic agents · CPC title
- A61K48/00Primary
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
the cells being hematopoietic, bone marrow derived or blood cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101658B2 cover?
- Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
- Who is the assignee on this patent?
- Contag Christopher H, Thorne Stephen, Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification A61K48/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).